Why EMs are more immune to COVID-19 disruption than DMs
GMO’s EM equity team makes a case for MSCI EM Index’s resilience and speedy recovery
July 30, 2020
Its IPO was overhyped but is it time to relook at SBI Cards?
Listing amidst a pandemic hurt its market cap, but analysts feel the SBI subsidiary could bounce back in FY22
Anishaa Kumar - July 02, 2020
Will we see further earnings downgrade post Q1FY21 results?
As the lockdown continues in several parts of the country, growth is barely picking up
July 16, 2020
Why Ashish Kacholia, Mukul Agrawal and Kedaara Capital are hot on Religare Enterprises
Despite its troubled past, its healthcare insurance business may turn out to be a dark horse
Anishaa Kumar - July 16, 2020
Clean stock market data. The question is, who pays for it?
Tijori Finance offers a float for those fearful of drowning in stock market data, but its business model remains unclear
Rishabh Bhatnagar - July 11, 2020
Is there more upside in store for pharma stocks?
Over the past year, the Nifty Pharma Index has gained 23% while the Nifty has declined by 11%
June 30, 2020
Veteran fund manager and CIO of HDFC AMC sells one-third of his stake in the company worth Rs.747 million
Shailaja Mohapatra - July 03, 2020
Will Moody's downgrade result in more FII outflows?
FIIs have YTD sold Rs.612 billion, but the latest negative rating might hurt investor sentiment again
June 05, 2020
What does Rakesh Jhunjhunwala see in Jubilant Life Sciences?
Within a year, the investing legend has doubled down on his latest pharma bet
Himanshu Kakkar - May 23, 2020
“This is 3-4x bigger than the 2008 crisis”
Despite the sharp correction in the Indian market, Sridhar Sivaram, investment director at Enam Holdings, has decided to stay away till volatility peaks out
April 25, 2020